An innovative life sciences company, INCELL is developing an oral vaccine business utilizing its proprietary platform technology for stimulating mucosal immunity. The Company’s in-depth understanding of and experience with nanotechnology, biotechnology and the mucosal immune system have enabled the development of its oral vaccine technology. We believes that our oral vaccine technology, which delivers the immunogenic vaccine material to the mouth and small intestine, thereby creating both mucosal and systemic immunity, offers competitive advantages over other vaccines. These advantages include efficacy gained from creating mucosal immunities, cost, storage and stability.
